Ioannis Papayannopoulos

article

Characterising therapeutic antibodies and ADCs using mass spectrometry

Since the 1970s, the advent of biotechnology has resulted in…

24 August 2016 | By Ioannis A. Papayannopoulos (Celldex Therapeutics Inc.)

Since the 1970s, the advent of biotechnology has resulted in the development and commercialisation of many therapeutic proteins, including antibodies and antibody fragments, for the treatment of human diseases. Examples include antibody treatments for autoimmune diseases (for example, adalimumab [Humira®] for rheumatoid arthritis), cancers (such as trastuzumab [Herceptin®] for breast…

article

Mass Spectrometry: In-Depth Focus 2014

In this free-to-view Mass Spectrometry In-Depth Focus: Some tricks and…

15 April 2014 | By European Pharmaceutical Review

In this free-to-view Mass Spectrometry In-Depth Focus: Some tricks and tools for structural characterisation of natural products using Electrospray mass spectrometry, Mass spectrometry in the biopharmaceutical industry: from the mundane to the cutting edge, and Mass Spectrometry roundtable...